<DOC>
	<DOCNO>NCT01683552</DOCNO>
	<brief_summary>Itch common side effect anti-epidermal growth factor receptor antibody tyrosine kinase inhibitor . Investigators design pilot single-center phase II study evaluate effect Aprepitant , neurokinin receptor inhibitor , manage biological therapy-induced pruritus .</brief_summary>
	<brief_title>Aprepitant Management Biological Therapies-related Severe Pruritus</brief_title>
	<detailed_description>Investigators enroll patient affect solid tumor present itch refractory standard treatment ( `` refractory group '' ) patient receive treatment pruritus ( `` naïve group '' ) . The intensity itch evaluate Visual Analogue Scale ( VAS ) score . In refractory group Aprepitant ( 125 mg day 1 ; 80 mg day 3 ; 80 mg day 5 ) administer least 1 week standard systemic treatment . In naïve group , Aprepitant administer first onset severe pruritus . The primary end point evaluate effect aprepitant manage pruritus naive refractory group .</detailed_description>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>histologically confirm diagnosis solid tumor treatment antiEGFR antibody TKIs first onset severe pruritus treatment ( ≥7 Visual Analogue Scale ( VAS ) score ) oral treatment antimycotic 4 week precede enrolment topical treatment previous 2 week concomitant , chronic renal hepatic insufficiency , skin infection dermatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>ITCH</keyword>
</DOC>